Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of AR...
Novavax targets approval for the COVID-19 vaccine in the US Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The aim hints the U.S. could join the U.K...
Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If every...
Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas.&nb...
AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised U...
Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its...
Patent protection and expiration is one of the hot topics in the healthcare industry. P...
Food Allergies is a major concern for a wide spectrum of populations globally. Accordin...
Bone densitometers are the diagnostic systems with an enhanced X-ray technology known a...
Today, the most important factor affecting the world’s economy is the Global Pharmaceut...
It's no longer startling to learn that the best-performing surgeon at a hospital isn't ...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
.png)
